- Home
- RNP vs RGNX Comparison
RNP vs RGNX Comparison
Compare RNP & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNP | RGNX |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 984.5M | 793.5M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | RNP | RGNX |
|---|---|---|
| Price | $18.52 | $7.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $23.73 |
| AVG Volume (30 Days) | 109.1K | ★ 1.0M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 7.94% | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $18.64 | $5.46 |
| 52 Week High | $22.33 | $16.19 |
Technical Indicators
Market Signals| Indicator | RNP | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 23.27 | 38.23 |
| Support Level | N/A | $7.12 |
| Resistance Level | $20.97 | $11.43 |
| Average True Range (ATR) | 0.24 | 0.44 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 0.00 | 29.14 |
Price Performance
Historical ComparisonAbout RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances. The Fund seeks to achieve its objectives through a portfolio of income producing common stock issued by REITs and preferred and other debt securities.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.